J&J Shares Fall Despite Drug Gains as MedTech Growth Lags
J&J beat third-quarter forecasts and lifted its sales outlook, but shares slid more than 5% as medtech growth lagged while drug sales rose 7.7%.
1 h ago8 min read
J&J beat third-quarter forecasts and lifted its sales outlook, but shares slid more than 5% as medtech growth lagged while drug sales rose 7.7%.